OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study

Abstract

citation ID: jjad212.0005 OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn's Disease: results of the treat-through VIVID 1 study Background: Mirikizumab (miri) is a selective IL23p19 monoclonal antibody approved for the treatment of ulcerative colitis. The primary focus of the VIVID-1 trial (NCT03926130) was to demonstrate the efficacy and safety of mirikizumab (miri) compared to placebo (PBO) in patients (pts) with moderate-to-severe Crohn's disease. Here we present primary efficacy and safety of miri compared to placebo (PBO) up to Week 52 (W52) from the Phase 3, randomised, double-blind, double-dummy, active-and PBO-controlled, treat-through VIVID-1 study.